What we’re looking at
Migraine affects roughly one billion people worldwide, making it one of the most disabling neurological conditions on the planet. For decades, triptans—drugs that constrict blood vessels and block pain pathways—have been the mainstay of acute migraine treatment. But a new class of preventive medications has entered the scene: monoclonal antibodies targeting calcitonin gene-related peptide (CGRP), a signaling molecule heavily implicated in migraine pathophysiology [PMID 34635045]. These therapies represent the culmination of 40 years of research into the trigeminovascular system, the network of nerves and blood vessels surrounding the brain that becomes hyperactive during migraine attacks.
This evidence review synthesizes recent meta-analyses and systematic reviews comparing the effectiveness and safety of triptans versus CGRP-targeted antibodies for both acute treatment and prevention of migraine. We focus particularly on how these medications perform in challenging scenarios like menstrual migraine and medication-overuse headache, and which patient characteristics predict better or worse responses.
The evidence — what studies actually found
Acute treatment effectiveness
For stopping a migraine attack once it starts, triptans remain highly effective. A 2024 meta-analysis of 26 randomized controlled trials found that among acute treatments for menstrual migraine—a particularly severe form affecting about 25% of women with migraine—sumatriptan and lasmiditan (a newer agent) demonstrated superior pain relief both at 2 hours (odds ratio 4.62) and 24 hours (odds ratio 4.81) compared to placebo [PMID 39227797]. This means patients were roughly 4.6 times more likely to experience meaningful pain relief with these medications than with dummy pills.
Triptans combined with other analgesics also outperformed placebo consistently across acute menstrual migraine trials. The evidence establishes triptans as effective first-line treatments for stopping migraine attacks, though individual response varies considerably.
Preventive treatment: CGRP antibodies pull ahead
When it comes to preventing migraine attacks before they start, CGRP-targeted monoclonal antibodies show particular promise. Four such antibodies are currently available: erenumab (which blocks the CGRP receptor), and eptinezumab, fremanezumab, and galcanezumab (which bind to CGRP itself) [PMID 35162776].
The 2024 menstrual migraine meta-analysis found that while frovatriptan showed effectiveness in preventing headache recurrence, CGRP antibodies—specifically erenumab and galcanezumab—displayed significantly greater preventive benefits in reducing monthly headache days compared to triptans [PMID 39227797]. This represents a meaningful advantage: rather than taking medication repeatedly to stop individual attacks, patients receive injections every month or three months that reduce attack frequency overall.
A separate systematic review examining medication overuse headache (MOH)—a rebound headache condition affecting patients who take acute migraine medications too frequently—found that CGRP antibodies helped 44% more patients transition from medication overuse status back to normal use patterns compared to placebo (relative risk 1.44, 95% CI 1.31-1.59) [PMID 38564060]. This is particularly significant because MOH can trap patients in a vicious cycle of worsening headaches and escalating medication use.
Predicting who responds
Not everyone responds equally to CGRP antibodies. A 2023 scoping review and meta-analysis of 38 real-world studies identified several predictors of treatment response [PMID 37513846]. Patients more likely to benefit from CGRP antibodies include those who:
- Respond well to triptans for acute attacks
- Experience unilateral (one-sided) pain with or without autonomic symptoms like tearing or nasal congestion
Conversely, patients less likely to respond include those with:
- Obesity
- Interictal allodynia (pain sensitivity between migraine attacks)
- Daily persistent headaches
- Previous failure of multiple preventive medications
- Psychiatric comorbidities including depression
These patterns suggest that CGRP antibodies work best in patients whose migraine follows a more “classic” presentation and who haven’t developed complications from chronic headache conditions.
How it might work — biological mechanisms
The theoretical foundation for both triptans and CGRP-targeted therapies rests on decades of research into the trigeminovascular system. This system comprises sensory nerve fibers that innervate blood vessels in the meninges (the protective membranes surrounding the brain). When activated, these fibers release CGRP, a potent vasodilator and pain signaling molecule [PMID 34635045].
The triptan mechanism
Triptans primarily work by activating serotonin receptors (specifically 5-HT1B and 5-HT1D subtypes) on blood vessels and nerve endings. This activation causes blood vessels to constrict and reduces the release of inflammatory neuropeptides, including CGRP. Triptans also block pain signal transmission in the trigeminal nucleus, a relay station in the brainstem where migraine pain signals are processed. The catch is that triptans must be taken during an attack to be effective—they don’t prevent the trigeminovascular system from activating in the first place.
The CGRP antibody mechanism
CGRP monoclonal antibodies take a different approach. These large protein molecules circulate in the bloodstream and either bind directly to CGRP molecules (eptinezumab, fremanezumab, galcanezumab) or block the CGRP receptor on nerve and vessel cells (erenumab). By neutralizing CGRP signaling continuously, these antibodies raise the threshold for migraine activation [PMID 35162776]. They don’t stop attacks already in progress, but they reduce the frequency and severity of new attacks over time.
The antibodies are too large to cross the blood-brain barrier in significant amounts, so they primarily act on peripheral nerves and vessels. This peripheral action appears sufficient to prevent migraine, supporting the theory that migraine attacks originate in peripheral trigeminovascular structures rather than solely in the brain.
Why triptans help with medication overuse
The finding that CGRP antibodies particularly help patients overusing triptans (relative risk 1.71) but not those overusing simple analgesics like acetaminophen or ibuprofen (relative risk 1.10, not statistically significant) is intriguing [PMID 38564060]. One possible explanation is that triptan overuse may specifically sensitize CGRP pathways, creating a rebound effect that CGRP antibodies can interrupt. Simple analgesics likely cause medication overuse headache through different mechanisms not directly involving CGRP, making CGRP antibodies less effective for this subgroup.
Where the evidence is strong (and weak)
Strong evidence
The evidence base for both triptans and CGRP antibodies rests on numerous high-quality randomized controlled trials. The acute effectiveness of triptans has been established through decades of research across diverse patient populations. Similarly, phase 3 trials for all four CGRP antibodies demonstrated clear efficacy in reducing monthly migraine days, with effect sizes that are clinically meaningful—typically 3-4 fewer migraine days per month compared to placebo.
The meta-analyses reviewed here [PMID 39227797, PMID 38564060] followed rigorous systematic review methodology, pre-registered their protocols, and included only randomized trials, minimizing bias. Sample sizes were substantial, providing adequate statistical power to detect meaningful differences.
Moderate evidence
The comparative effectiveness data—directly comparing triptans to CGRP antibodies—is less robust because few head-to-head trials exist. Most conclusions about relative effectiveness come from indirect comparisons across different trials, which is less reliable than direct comparison in the same study population. The 2024 menstrual migraine review [PMID 39227797] synthesized evidence from 26 trials, but these used varying placebo groups, follow-up durations, and outcome definitions.
The predictor analysis [PMID 37513846] drew primarily on real-world observational studies rather than randomized trials. While these studies reflect actual clinical practice, they’re susceptible to confounding—obesity, depression, and previous treatment failures tend to cluster together, making it difficult to isolate which factors truly drive poor response versus which merely correlate with it.
Weak evidence
We still lack solid evidence on several clinically important questions: Which patients should try triptans first versus proceeding directly to CGRP antibodies? How long should patients try CGRP antibodies before concluding they don’t work? Can triptans and CGRP antibodies be safely combined, and does combination provide added benefit? The reviewed studies don’t adequately address these questions.
Additionally, most trials followed patients for 12-24 weeks. Long-term safety and effectiveness data beyond one year remain limited, particularly for the newest agents. The protocol paper [PMID 35162776] acknowledges this gap and proposes including real-world studies to supplement trial data, but real-world studies introduce their own biases.
Practical takeaways
Based on current evidence, here’s what patients and clinicians should know:
For acute migraine treatment: Triptans remain first-line therapy for most patients. Sumatriptan and the newer lasmiditan show particularly strong evidence for rapid pain relief. Taking triptans early in an attack, before pain becomes severe, improves effectiveness. However, triptans shouldn’t be used more than 9-10 days per month to avoid medication overuse headache.
For migraine prevention: CGRP antibodies offer advantages over daily oral preventives (like topiramate or propranolol) for many patients, particularly those who struggle with side effects or medication adherence. Monthly or quarterly injections are more convenient than daily pills. The evidence suggests CGRP antibodies reduce monthly migraine days more effectively than triptans used preventively.
For menstrual migraine: Both acute treatment with sumatriptan and short-term prevention with frovatriptan around menstruation show good evidence. For women with frequent menstrual migraines, CGRP antibodies (erenumab or galcanezumab) offer continuous prevention.
For medication overuse headache: CGRP antibodies help patients reduce triptan overuse more effectively than trying to stop “cold turkey” or switching to other preventives. The evidence is less clear for patients overusing simple analgesics.
Predicting response: Patients who respond well to triptans acutely, experience classic unilateral migraine with autonomic features, and don’t have obesity, depression, or daily headache appear most likely to benefit from CGRP antibodies. However, these are tendencies, not absolute rules—individual trial remains the gold standard.
Limitations of this review
This synthesis reviewed five meta-analyses and systematic reviews rather than individual trials. While this approach provides a broad overview of the evidence, it means we’re analyzing summaries of summaries, which can obscure important details about individual studies.
The included reviews used different outcome measures: some reported odds ratios, others relative risks, and still others mean differences in headache days. This heterogeneity makes direct comparison challenging. We also don’t have consistent information about adverse effects—the reviews focused primarily on effectiveness rather than safety.
Publication bias is a concern: negative trials are less likely to be published, potentially inflating apparent treatment effects. The predictor analysis [PMID 37513846] particularly notes inconsistency across studies examining the same predictors, suggesting potential selective reporting.
Finally, CGRP antibodies are expensive—often $6,000-8,000 per year in the United States without insurance coverage. None of the reviewed studies addressed cost-effectiveness, which significantly impacts real-world treatment decisions. The evidence on clinical effectiveness tells only part of the story when medications carry a 100-fold price difference.
Bottom line
Triptans and CGRP-targeted antibodies represent complementary tools in migraine management, not competing alternatives. Triptans excel at stopping acute attacks quickly and remain first-line therapy for most patients when used appropriately. CGRP antibodies offer superior prevention, particularly for patients with frequent migraines, those experiencing medication overuse with triptans, and those who’ve struggled with traditional oral preventives.
The evidence base for both classes is robust from a short-term efficacy standpoint, built on multiple high-quality randomized trials. CGRP antibodies represent a genuine therapeutic advance, validated by 40 years of basic research into migraine pathophysiology. However, individual response varies considerably, and emerging evidence on predictors of response may eventually enable more personalized treatment selection.
Key gaps remain: we need head-to-head comparative trials, longer-term safety data, better understanding of why some patients don’t respond, and cost-effectiveness analyses to guide resource allocation. For now, treatment selection depends on migraine frequency, previous treatment responses, comorbidities, patient preferences, and access to medications—a multifactorial decision best made collaboratively between patients and headache specialists.
FAQ: Migraine Medications – Triptans vs. CGRP Antibodies
What is the main difference between triptans and CGRP antibodies for migraine?
Triptans are acute treatments designed to stop a migraine attack once it has started, typically taken as pills, nasal sprays, or injections during an attack. CGRP antibodies, on the other hand, are preventive medications administered as injections every month or three months to reduce how often migraine attacks occur. Research shows triptans like sumatriptan remain highly effective for stopping active attacks, with patients 4.6 times more likely to experience pain relief within 2 hours compared to placebo (PMID 39227797). Meanwhile, CGRP antibodies like erenumab and galcanezumab demonstrate superior effectiveness in reducing monthly migraine days for prevention (PMID 39227797, PMID 35162776). Most patients use these medications for different purposes rather than choosing one over the other.
How do CGRP antibodies actually prevent migraines?
CGRP antibodies work by targeting calcitonin gene-related peptide (CGRP), a signaling molecule that becomes elevated during migraine attacks and contributes to the activation of the trigeminovascular system—the network of nerves and blood vessels surrounding the brain involved in migraine pathophysiology (PMID 34635045). These monoclonal antibodies either block CGRP from binding to its receptor (like erenumab) or bind directly to CGRP itself (like eptinezumab, fremanezumab, and galcanezumab), preventing it from triggering migraine-related inflammatory responses (PMID 35162776). This represents the culmination of 40 years of research into migraine mechanisms, offering the first preventive treatments specifically designed based on migraine biology rather than repurposed medications.
Are triptans still recommended now that CGRP antibodies are available?
Yes, triptans remain the first-line treatment for acute migraine attacks and are not being replaced by CGRP antibodies. These medication classes serve complementary rather than competing roles: triptans address active attacks while CGRP antibodies reduce attack frequency. Evidence from 2024 confirms that triptans like sumatriptan continue to provide superior pain relief for stopping migraine attacks, including particularly severe menstrual migraines affecting about 25% of women with migraine (PMID 39227797). Many patients benefit from using both types of medications—CGRP antibodies to reduce how often attacks occur, and triptans to treat breakthrough attacks that do happen. The choice depends on individual patient characteristics, attack frequency, and treatment goals.
Which medication works better for menstrual migraine specifically?
For acute treatment of menstrual migraine attacks, sumatriptan and similar medications demonstrate strong effectiveness, with odds ratios of 4.62 for 2-hour pain relief and 4.81 for 24-hour relief compared to placebo (PMID 39227797). For prevention of menstrual migraine, CGRP antibodies like erenumab and galcanezumab show significantly greater benefits in reducing monthly headache days compared to triptans used preventively (PMID 39227797). Frovatriptan, a longer-acting triptan, has shown effectiveness in preventing headache recurrence during menstrual periods specifically. The optimal approach often involves CGRP antibodies for overall prevention combined with triptans available for acute treatment during menstrual periods when attacks may still occur despite preventive therapy.
How quickly do CGRP antibodies start working compared to triptans?
Triptans work rapidly for acute attacks, with most patients experiencing pain relief within 2 hours of taking the medication (PMID 39227797), making them suitable for stopping attacks in progress. CGRP antibodies, being preventive medications, work on a different timeline—they are administered monthly or quarterly and typically require several weeks to months to demonstrate their full preventive effect by gradually reducing attack frequency. This fundamental difference reflects their distinct mechanisms: triptans constrict blood vessels and block pain pathways during active attacks, while CGRP antibodies modulate the underlying biology that triggers attacks. Patients beginning CGRP antibody therapy should maintain acute treatments like triptans available during the initial months while preventive effects develop.
Studies referenced
-
PMID 39227797 — Meta-analysis of 26 RCTs comparing acute and preventive treatments for menstrual migraine, finding sumatriptan/lasmiditan superior for acute treatment and CGRP antibodies superior for prevention.
-
PMID 35162776 — Protocol for systematic review comparing four CGRP monoclonal antibodies (erenumab, eptinezumab, fremanezumab, galcanezumab) on monthly migraine days, headache impact, and triptan use.
-
PMID 37513846 — Scoping review and meta-analysis of 38 real-world studies identifying predictors of response to CGRP antibodies, including positive predictors (triptan response, unilateral pain) and negative predictors (obesity, depression, medication overuse).
-
PMID 38564060 — Meta-analysis of phase 3 RCTs examining whether CGRP antibodies help patients transition from medication overuse to normal use, finding significant benefit overall (RR 1.44) and particularly for triptan overuse (RR 1.71).
-
PMID 34635045 — Review of 40 years of CGRP research in migraine pathophysiology and treatment development, summarizing the work of the 2021 Brain Prize winners who established the trigeminovascular theory of migraine.